Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1976 3
1977 2
1978 3
1979 2
1980 1
1981 3
1982 1
1983 4
1984 4
1985 10
1986 7
1987 11
1988 8
1989 7
1990 7
1991 6
1992 8
1993 8
1994 9
1995 4
1996 12
1997 9
1998 10
1999 14
2000 10
2001 11
2002 13
2003 11
2004 7
2005 9
2006 9
2007 9
2008 8
2009 9
2010 9
2011 15
2012 5
2013 10
2014 9
2015 8
2016 8
2017 10
2018 9
2019 11
2020 10
2021 8
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

347 results

Results by year

Filters applied: . Clear all
Page 1
CD38 antibodies in multiple myeloma: back to the future.
van de Donk NWCJ, Richardson PG, Malavasi F. van de Donk NWCJ, et al. Among authors: malavasi f. Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8. Blood. 2018. PMID: 29118010 Free article. Review.
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F, Manier S, Chang-Ki Min, Ocio EM, Pawlyn C, Perrot A, Quach H, Richter J, Spicka I, Yong K, Richardson PG. Leleu X, et al. Among authors: malavasi f. Ann Hematol. 2022 Oct;101(10):2123-2137. doi: 10.1007/s00277-022-04917-5. Epub 2022 Aug 9. Ann Hematol. 2022. PMID: 35943588 Free PMC article. Review.
Editorial: Immunotherapy in Multiple Myeloma.
Giuliani N, Malavasi F. Giuliani N, et al. Among authors: malavasi f. Front Immunol. 2019 Aug 14;10:1945. doi: 10.3389/fimmu.2019.01945. eCollection 2019. Front Immunol. 2019. PMID: 31475006 Free PMC article. No abstract available.
A Purinergic Trail for Metastases.
Ferrari D, Malavasi F, Antonioli L. Ferrari D, et al. Among authors: malavasi f. Trends Pharmacol Sci. 2017 Mar;38(3):277-290. doi: 10.1016/j.tips.2016.11.010. Epub 2016 Dec 16. Trends Pharmacol Sci. 2017. PMID: 27989503 Review.
A phylogenetic view of the leukocyte ectonucleotidases.
Ferrero E, Faini AC, Malavasi F. Ferrero E, et al. Among authors: malavasi f. Immunol Lett. 2019 Jan;205:51-58. doi: 10.1016/j.imlet.2018.06.008. Epub 2018 Jun 26. Immunol Lett. 2019. PMID: 29958894 Review.
Antibody mimicry, receptors and clinical applications.
Horenstein AL, Chillemi A, Quarona V, Zito A, Mariani V, Faini AC, Morandi F, Schiavoni I, Ausiello CM, Malavasi F. Horenstein AL, et al. Among authors: malavasi f. Hum Antibodies. 2017;25(3-4):75-85. doi: 10.3233/HAB-160305. Hum Antibodies. 2017. PMID: 28035914 Review.
CD38 as a multifaceted immunotherapeutic target in CLL.
Paulus A, Malavasi F, Chanan-Khan A. Paulus A, et al. Among authors: malavasi f. Leuk Lymphoma. 2022 Oct;63(10):2265-2275. doi: 10.1080/10428194.2022.2090551. Epub 2022 Aug 17. Leuk Lymphoma. 2022. PMID: 35975791 Review.
CD38 and bone marrow microenvironment.
Chillemi A, Zaccarello G, Quarona V, Lazzaretti M, Martella E, Giuliani N, Ferracini R, Pistoia V, Horenstein AL, Malavasi F. Chillemi A, et al. Among authors: malavasi f. Front Biosci (Landmark Ed). 2014 Jan 1;19(1):152-62. doi: 10.2741/4201. Front Biosci (Landmark Ed). 2014. PMID: 24389178 Free article. Review.
CD38 in the age of COVID-19: a medical perspective.
Horenstein AL, Faini AC, Malavasi F. Horenstein AL, et al. Among authors: malavasi f. Physiol Rev. 2021 Oct 1;101(4):1457-1486. doi: 10.1152/physrev.00046.2020. Epub 2021 Mar 31. Physiol Rev. 2021. PMID: 33787351 Free PMC article. Review.
347 results